Chemoradiotherapy of NSCLC Stage IIIB
To evaluate the best timing of the concomitant chemoradiotherapy among patients with NSCLC stage III not resectable treated by concomitant chemo-radiotherapy, either preceded by a induction chemotherapy, or followed by a consolidation chemotherapy.
NSCLC Stage IIIB|Concomitant Radiochemotherapy
DRUG: Paclitaxel, vinorelbine, cisplatin
Objective response rate
Overall survival|Time to progression|Relapse rate (local control)|Safety
Chemotherapy:

C = Cisplatine : 80 mg/m² P = Paclitaxel : 200 mg/m² N = Vinorelbine : 15 mg/m²

Radiotherapy:

66 Gy with 33 fractions (2 Gy/fraction, 1 fraction/day, 6,5 weeks) High energy Photons X (\>= 9MV)